INPP5D — Inositol Polyphosphate-5-Phosphatase D (SHIP1)

INPP5D — Inositol Polyphosphate-5-Phosphatase D (SHIP1)

Pathway Diagram

Introduction

Inpp5D — Inositol Polyphosphate 5 Phosphatase D (Ship1) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

INPP5D — Inositol Polyphosphate-5-Phosphatase D (SHIP1)

Pathway Diagram

Introduction

Inpp5D — Inositol Polyphosphate 5 Phosphatase D (Ship1) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-gene"> [@maxwell2020]
<div class="infobox-header">INPP5D</div> [@kerdiles2009]
<table> [@takaesu2012]
<tr><td class="infobox-label">Full Name</td><td>Inositol Polyphosphate-5-Phosphatase D</td></tr> [@orr2013]
<tr><td class="infobox-label">Protein</td><td>SHIP1 (SH2-containing Inositol 5'-Phosphatase 1)</td></tr> [@heneka2015]
<tr><td class="infobox-label">Chromosome</td><td>2q37.1</td></tr> [@pubmed]
<tr><td class="infobox-label">NCBI Gene ID</td><td><a href="https://www.ncbi.nlm.nih.gov/gene/3635" target="_blank">3635</a></td></tr> [@pubmeda]
<tr><td class="infobox-label">OMIM</td><td><a href="https://www.omim.org/entry/601582" target="_blank">601582</a></td></tr> [@pubmedb]
<tr><td class="infobox-label">Ensembl</td><td><a href="https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000168918" target="_blank">ENSG00000168918</a></td></tr> [@pubmedc]
<tr><td class="infobox-label">UniProt (protein)</td><td><a href="https://www.uniprot.org/uniprot/Q92835" target="_blank">Q92835</a></td></tr> [@pubmedd]
<tr><td class="infobox-label">Protein Size</td><td>1,188 amino acids (~145 kDa)</td></tr> [@pubmede]
<tr><td class="infobox-label">Associated Diseases</td><td>[Alzheimer's Disease](/diseases/alzheimers)</td></tr> [@pubmedf]
</table> [@pubmedg]
</div> [@horai2018] [@pubmedh]

Overview

INPP5D encodes SHIP1 (SH2-containing Inositol 5'-Phosphatase 1), a lipid phosphatase predominantly expressed in hematopoietic cells and [microglia](/entities/microglia). Because INPP5D expression in the [@pubmedi]
brain is restricted to [microglia](/cell-types/microglia), this genetic association directly implicates microglial signaling dysfunction in AD pathogenesis. INPP5D functions downstream of [TREM2](/proteins/trem2-protein) and [@mdpi2073]
Toll-like receptors, placing it at the intersection of two major microglial signaling pathways implicated in neurodegeneration. [@kerdiles2009] [@allen]

Protein Structure and Domains

SHIP1 is a 1,188-amino acid protein (~145 kDa) containing several functionally critical domains: [@takaesu2012] [@allena]

• SH2 domain (N-terminal): Binds phosphotyrosine motifs on receptors and adaptor proteins, including the immunoreceptor tyrosine-based inhibitory motifs (ITIMs) of inhibitory receptors such as FcγRIIB. This domain mediates recruitment of SHIP1 to activated receptor complexes at the plasma membrane.
• Central phosphatase domain: Contains the catalytic 5'-phosphatase activity that hydrolyzes the 5'-phosphate from PI(3,4,5)P3 to generate PI(3,4)P2. [The catalytic domain requires Mg²⁺ as a cofactor. This is the domain that is frequently missing in the truncated SHIP1 protein found in AD brains ([Tsai et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33545218/)).
• C2 domain: Mediates calcium-dependent membrane binding, facilitating SHIP1 localization to PI(3,4,5)P3-enriched membrane domains.
• Proline-rich regions (C-terminal): Interact with SH3 domain-containing proteins, including Grb2 and the p85 subunit of PI3K, enabling SHIP1 integration into diverse signaling complexes.
• NPXY motifs (C-terminal): Serve as binding sites for the PTB domains of Shc and Dok family adaptors, linking SHIP1 to Ras/MAPK pathway regulation. [@orr2013]

Function

Phosphoinositide Signaling

SHIP1 is a key negative regulator of the PI3K/AKT pathway in myeloid cells: [@allenc]

• Substrate: Converts PI(3,4,5)P3 to PI(3,4)P2 through 5'-dephosphorylation
• Signaling output: Reduces AKT activation, dampening cell survival, proliferation, and inflammatory signaling
• Receptor coupling: Acts downstream of [TREM2](/proteins/trem2-protein), Fc receptors, colony-stimulating factor 1 receptor (CSF1R), and Toll-like receptors (TLRs)
• Microglial state regulation: SHIP1 activity modulates the transition between homeostatic and [disease-associated microglia (DAM)](/disease-associated-microglia-(dam)))))) states

Microglial Functions Regulated by SHIP1

SHIP1 controls multiple microglial functions relevant to neurodegeneration: [@brainspan]

• Phagocytosis: SHIP1 restrains complement receptor-mediated phagocytosis; its loss leads to enhanced but dysregulated engulfment of synapses and debris
• Inflammasome activation: SHIP1 inhibits [NLRP3](/mechanisms/nlrp3-inflammasome) inflammasome] assembly and activation. Reduction of SHIP1 activity induces [NLRP3](/mechanisms/nlrp3-inflammasome)-dependent release of IL-1β and IL-18 ([Bhattacherjee et al., 2023](https://www.nature.com/articles/s41467-023-42819-w))
• Cytokine production: SHIP1 limits [NF-κB](/entities/nf-kb)-driven pro-inflammatory cytokine expression
• Synaptic pruning: Microglial SHIP1 limits complement-mediated synaptic pruning in the developing and adult [hippocampus](/brain-regions/hippocampus) ([Bhatt et al., 2024](https://www.sciencedirect.com/science/article/pii/S1074761324005132))
• Myelin debris clearance: SHIP1 modulates the rate of myelin phagocytosis, relevant to demyelinating conditions and white matter damage in AD
• Chemotaxis: SHIP1 influences microglial migration toward injury sites and amyloid plaques through regulation of PI3K-dependent cytoskeletal rearrangement

Disease Associations

Alzheimer's Disease GWAS Signal

INPP5D was identified as an AD risk locus in the large International Genomics of Alzheimer's Project (IGAP) meta-analysis of over 74,000 individuals ([Lambert et al., 2013](https://pubmed.ncbi.nlm.nih.gov/24162737/)). The risk variant rs35349669 is associated with increased AD risk (OR ≈ 1.08). Fine-mapping and functional genomic studies have further refined the INPP5D locus, identifying potential causal variants in microglial-specific enhancer regions that alter INPP5D expression levels. [@ncbi]

INPP5D Expression Changes in AD

The relationship between INPP5D expression and AD is complex and paradoxical: [@uniprot]

• Increased mRNA in AD: INPP5D mRNA expression is elevated in AD brains, correlating with amyloid plaque burden and disease severity ([Tsai et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33545218/))
• Plaque-associated upregulation: INPP5D expression is specifically increased in [microglia](/cell-types/microglia) surrounding amyloid plaques, suggesting a reactive microglial response
• Truncated protein: Despite increased mRNA, the predominant SHIP1 protein in AD brains is truncated and potentially dysfunctional, missing the critical phosphatase domain. This suggests a paradoxical loss of effective SHIP1 activity alongside elevated expression ([Tsai et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33545218/))
• Expression correlates with Braak stage: INPP5D mRNA is upregulated 2–3-fold in AD temporal [cortex](/brain-regions/cortex), with expression correlating with CERAD plaque score and Braak staging of tau]/proteins/tau] pathology

NLRP3 Inflammasome Connection

A landmark 2023 study demonstrated that reduction of INPP5D/SHIP1 activity directly activates the [NLRP3 inflammasome](/mechanisms/nlrp3-inflammasome) in human iPSC-derived [microglia](/cell-types/microglia) ([Bhattacherjee et al., 2023](https://www.nature.com/articles/s41467-023-42819-w)). This finding provides a mechanistic link between the INPP5D GWAS signal and [neuroinflammation](/mechanisms/neuroinflammation): [@omim]

• SHIP1 inhibition increases PIP3 levels and AKT phosphorylation in [microglia](/cell-types/microglia-neuroinflammation)
• Elevated PIP3 signaling promotes [NLRP3](/mechanisms/nlrp3-inflammasome) inflammasome assembly and caspase-1 activation
• Downstream IL-1β and IL-18 release drives neurotoxic inflammatory cascades
• This mechanism operates independently of classical [NLRP3](/mechanisms/nlrp3-inflammasome) priming signals

Complement-Mediated Synapse Loss

A 2024 study revealed that mice lacking microglial SHIP1 display increased complement-dependent synapse loss in the early postnatal brain ([Bhatt et al., 2024](https://www.sciencedirect.com/science/article/pii/S1074761324005132)): [@alzforum]

• SHIP1-deficient [microglia](/cell-types/microglia) show altered transcriptional signatures with enhanced phagocytic gene expression
• Excessive complement-mediated synaptic pruning occurs in the [hippocampus](/brain-regions/hippocampus)
• Cognitive defects in adulthood result from early postnatal SHIP1 depletion but not from later-stage depletion
• These findings suggest that SHIP1 dysfunction may contribute to the synaptic vulnerability observed in preclinical AD

Sex-Specific Effects

Loss of INPP5D has sex-specific effects on the brain transcriptome ([Bissel et al., 2024](https://pmc.ncbi.nlm.nih.gov/articles/PMC11350029/)): [@allend]

• Affected genes are enriched for neurodegeneration-related terms
• Female mice show more pronounced transcriptional changes following Inpp5d loss
• These findings suggest that INPP5D may contribute to the sex differences observed in AD risk and progression

Animal Model Studies

Conflicting Results Across AD Mouse Models

Studies using different AD mouse models have revealed context-dependent effects of INPP5D/SHIP1 manipulation, highlighting the complexity of its role in disease: [@ship]

• PSAPP model: In PSAPP mice, heterozygous Inpp5d reduction increased amyloid deposits by >66% in the [hippocampus](/brain-regions/hippocampus) at 6 months, along with increased plaque-associated [microglia](/cell-types/microglia) and elevated markers of [neuroinflammation](/mechanisms/neuroinflammation) ([Castranio et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36448627/)). This suggests SHIP1 may limit plaque formation in some contexts.
• 5xFAD model: In contrast, conditional deletion of Inpp5d in [microglia](/cell-types/microglia) of 5xFAD mice at 3 weeks of age led to substantially enhanced microglial recruitment to [amyloid-beta](/proteins/amyloid-beta)/proteins/[amyloid plaques, improved plaque containment and [Aβ](/proteins/amyloid-beta-protein) engulfment, decreased microglial ramification, and marked amelioration of neuritic dystrophy — without changes in total plaque burden ([Lin et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37061460/)). This indicates SHIP1 normally restricts neuroprotective microglial responses.
• Model reconciliation: The contradictory impacts likely reflect differences in timing of Inpp5d deletion relative to disease onset, the specific AD mouse model used, and the distinction between acute inflammasome activation (detrimental) versus enhanced microglial plaque engagement (beneficial) ([Lin et al., 2023](https://pmc.ncbi.nlm.nih.gov/articles/PMC10685641/)).

Key Insights from Animal Studies

These findings reveal a dual role for SHIP1 in AD: it restrains beneficial microglial phagocytic responses to plaques (loss is protective) while simultaneously preventing harmful inflammasome-driven neuroinflammation (loss is detrimental). The net effect depends on disease stage, cellular context, and the balance between these opposing functions.

Therapeutic Targeting

SHIP1 Inhibition Strategy

Given that SHIP1 deletion enhances neuroprotective microglial responses in amyloid pathology, SHIP1 inhibition has emerged as a therapeutic strategy for AD:

• Small molecule inhibitors: Multiple academic and pharmaceutical groups have developed SHIP1 inhibitor compounds. A pyridyl-pyrazole-piperidine scaffold (compound 32) showed promising results in preclinical models: oral administration in an amyloidosis mouse model achieved brain exposure sufficient to enhance microglial uptake of myelin/membrane debris and fibrillar [amyloid/proteins/amyloid, alter gene expression, and reduce IL-1β levels as a pharmacodynamic marker of microglial activation ([Bhattacherjee et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41509252/)).
• Target engagement: Cellular thermal shift assays using full-length SHIP1 have been developed to assess compound-target engagement, enabling structure-activity relationship optimization ([Jesudason et al., 2023](https://pmc.ncbi.nlm.nih.gov/articles/PMC10655782/)).
• Enhanced phagocytosis: In high-content cellular imaging assays, SHIP1 inhibitors enhanced microglial uptake of myelin debris and fibrillar amyloid, phenocopying genetic models with reduced SHIP1 expression.

SHIP1 Agonism Strategy

Paradoxically, SHIP1 agonism has also been proposed as a therapeutic approach, based on the inflammasome-activating consequences of SHIP1 loss:

• Restoring or enhancing SHIP1 activity could suppress [NLRP3](/mechanisms/nlrp3-inflammasome) inflammasome-driven [neuroinflammation](/mechanisms/neuroinflammation) without compromising baseline microglial surveillance
• This approach may be particularly relevant for patients with the truncated SHIP1 protein found in AD brains
• The choice between inhibition and agonism strategies may ultimately depend on disease stage: inhibition to enhance plaque clearance early, agonism to reduce neuroinflammation later

Challenges and Considerations

• SHIP1 is expressed in all hematopoietic lineages; systemic inhibition could affect peripheral immune function
• [microglia](/cell-types/microglia) delivery or conditional activation strategies may be required
• The timing of intervention relative to disease progression is critical given the dual role of SHIP1
• SHIP1 inhibition could exacerbate [complement-mediated synapse loss](/mechanisms/complement-mediated-synapse-loss), requiring combination approaches

Expression

Brain-Specific Expression

In the CNS, INPP5D expression is restricted to myeloid lineage cells:

• [microglia](/cell-types/microglia): The primary cell type expressing INPP5D in the brain; expression is enriched in homeostatic microglia and dynamically regulated upon activation
• Perivascular macrophages: Express INPP5D at the neurovascular interface
• [neurons](/entities/neurons) and [astrocytes](/cell-types/astrocytes): Do not express INPP5D under normal conditions
• Border-associated macrophages: INPP5D is expressed in meningeal and choroid plexus macrophages

Disease-Associated Changes

• INPP5D mRNA is upregulated 2–3-fold in AD temporal [cortex](/brain-regions/cortex)
• Expression correlates with Braak stage and CERAD plaque score
• Multiple isoforms exist, with differential regulation in AD
• Single-cell RNA-seq studies confirm INPP5D as a marker distinguishing microglia from other brain cell types

Allen Brain Atlas Resources

• [Allen Human Brain Atlas — INPP5D expression](https://human.brain-map.org/microarray/search/show?search_term=INPP5D)

Brain Atlas Resources

• [Allen Brain Atlas](https://brain-map.org)
• [Allen Human Brain Atlas: INPP5D search](https://human.brain-map.org/microarray/search/show?search_term=INPP5D)
• [Allen Mouse Brain Atlas: INPP5D search](https://mouse.brain-map.org/search/index.html?query=INPP5D)
• [Allen Cell Type Atlas](https://portal.brain-map.org/atlases-and-data/rnaseq)
• [BrainSpan Developmental Transcriptome](https://www.brainspan.org)

See Also

• [Genes Index](/genes)
• [Proteins Index](/proteins)
• [Genetics](/mechanisms/genetics)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [Allen Brain Atlas](https://www.brain-map.org/)

Background

The study of Inpp5D — Inositol Polyphosphate 5 Phosphatase D (Ship1) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

Pathway Diagram

The following diagram shows the key molecular relationships involving INPP5D — Inositol Polyphosphate-5-Phosphatase D (SHIP1) discovered through SciDEX knowledge graph analysis: